Results 151 to 160 of about 10,664 (186)

Long-Term Safety of Anti-Interleukin-1 Medications in Children with Rheumatic Diseases: a Systematic Review. [PDF]

Paediatr Drugs
Isa M, Tiller GM, Liew DFL, Renton WD.
europepmc   +1 more source

Comparative effectiveness and safety of systemic therapies for treatment-naïve, PD-L1 expression <1% advanced NSCLC: a systematic review and network meta-analysis. [PDF]

Transl Lung Cancer Res
Zhou M, Huang J, Jin Z, Hao Q, Li X, Yu K, Sun K, Zhao X, Zhang M, Wang G, Cheng Y.   +10 more
europepmc   +1 more source

Targeted Anti-Inflammatory Therapy in Cardiovascular Events: Challenges and Opportunities. [PDF]

J Clin Hypertens (Greenwich)
Ma T, Wang L, Yan X, Li F.
europepmc   +1 more source

Optimal Medical Therapy Targeting Lipids and Inflammation for Secondary Prevention in Patients Undergoing Percutaneous Coronary Intervention. [PDF]

J Clin Med
Forzano I, Florimonte D, Narciso V, Canonico ME, Castiello DS, Manzi L, Cristiano S, Spinelli A, Vallone DM, D'Alconzo D, Semplice F, Paolillo R, Giugliano G, Cesaro A, Gragnano F, Calabrò P, Esposito G, Gargiulo G.   +17 more
europepmc   +1 more source

Sensorineural hearing loss in anti-interleukin-1 treated CAPS patients: risk factors and real-life barriers-an observational study. [PDF]

Rheumatology (Oxford)
Satirer Ö, Tropitzsch A, Koitschev A, Hospach T, Benseler SM, Benseler SM, Kuemmerle-Deschner JB.   +6 more
europepmc   +1 more source

Inflammation-modulating agents in chronic limb-threatening ischemia: a narrative review of therapeutic potential and future directions. [PDF]

Ann Med Surg (Lond)
Gaur A, Dike P, Mayowa T, Mekowulu FC, Abdulkader A, Rao MS, Shola A, Ajala P, Oluwatobi O, Abraham IC, Kokori E, Olatunji G, Aderinto N.   +12 more
europepmc   +1 more source